Bg. Xing et al., Binding properties of an orally active platinum anti-tumor drug JM216 withmetallothionein in vivo, BIOMETALS, 13(3), 2000, pp. 203-208
The abilities of the orally active platinum anti-tumor drug JM216 [trans-bi
s-acetato-cis-dichloroammine (cyclohexylamine) platinum (IV)] to induce the
biosynthesis of metallothionein (MT) were investigated in rabbits given or
al administrations or injections s. c. It is revealed that oral administrat
ion of JM216 can induce the MT synthesis in the liver but not in the kidney
. The hepatic MT contained 7.11 +/- 0.11 Zn and only little Pt or Cu. Injec
tions of JM216 to rabbits can greatly elevate the MT levels in the liver, b
ut increase the renal MT levels only slightly. The MT content as well as Pt
concentration in the liver was much higher than that in the kidney. The me
tal stoichiometry in the purified renal MT was determined to be 4.41 +/- 0.
04 Zn, 0.36 +/- 0.11 Pt and 2.50 +/- 0.18 Cu per mole protein. The hepatic
MT was still characterized as Zn7MT. Both the treatment with oral administr
ation and injections s.c. cannot lead to the increase of Pt content in the
kidney. The oxidation state of platinum in the MT from the kidney was deter
mined to be +2 by X-ray photoelectron spectroscopy. As compared with zinc c
ompounds, JM216 was a very poor stimulator for MT biosynthesis in vivo. Pre
-injections with Zn(NO3)(2) significantly enhanced the MT levels as well as
the Pt concentration compared with that resulting from injections with JM2
16 alone. Based on the experimental data, the role of MT in relation to its
involvement in the metabolism and the mechanism of detoxification of Pt(IV
) complexes are discussed.